Germline Testing: The Therapeutic Biomarker You Can’t Afford to Miss

You may already be ordering germline testing at rates well above the national average — but across the U.S., most eligible patients still aren’t tested: Ovarian cancer: ~39% receive germline…

Continue ReadingGermline Testing: The Therapeutic Biomarker You Can’t Afford to Miss

Operationalizing Early Palliative Care: Systems, Codes, and Metrics for Oncology Success

You know palliative care isn’t an end-of-life intervention. It’s a proactive, evidence-based system that extends survival, preserves dose intensity, and minimizes avoidable treatment disruptions. So, here's the real question: How…

Continue ReadingOperationalizing Early Palliative Care: Systems, Codes, and Metrics for Oncology Success

The Immunotherapy Clock Has Moved

Checkpoint inhibitors are no longer reserved for late-stage salvage. The clearest signal from recent meetings and trials is this: the greatest survival benefit may be increasingly found in neoadjuvant and perioperative settings. This…

Continue ReadingThe Immunotherapy Clock Has Moved